Cargando…

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response

BACKGROUND: Multiple sclerosis is one of the most prevalent neurological diseases in young adults affecting over 2 million people worldwide. Alemtuzumab is a highly effective therapy in relapsing remitting MS. Alemtuzumab is a monoclonal CD52 antibody that proved its efficacy against an active compa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bierhansl, Laura, Ruck, Tobias, Pfeuffer, Steffen, Gross, Catharina C., Wiendl, Heinz, Meuth, Sven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Clinical Trial Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650051/ https://www.ncbi.nlm.nih.gov/pubmed/33324905 http://dx.doi.org/10.1186/s42466-019-0045-x

Ejemplares similares

ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
por: Ruck, Tobias, et al.
Publicado: (2016)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
por: Riepl, Ester, et al.
Publicado: (2018)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study
por: Masanneck, Lars, et al.
Publicado: (2023)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function
por: Kleffner, Ilka, et al.
Publicado: (2017)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

Cytotoxic CD8(+) T cells and CD138(+) plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies
por: Melzer, Nico, et al.
Publicado: (2012)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Thinking outside the box: non-canonical targets in multiple sclerosis
por: Bierhansl, Laura, et al.
Publicado: (2022)

Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease
por: Schröder, Jens B., et al.
Publicado: (2018)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Ocrelizumab initiation in patients with MS: A multicenter observational study
por: Ellwardt, Erik, et al.
Publicado: (2020)

Autoimmunity complicating SARS-CoV-2 infection in selective IgA-deficiency
por: Pfeuffer, Steffen, et al.
Publicado: (2020)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis()
por: Deppe, Michael, et al.
Publicado: (2013)

CD4(+)NKG2D(+) T Cells Exhibit Enhanced Migratory and Encephalitogenic Properties in Neuroinflammation
por: Ruck, Tobias, et al.
Publicado: (2013)

Correction: CD4(+)NKG2D(+) T Cells Exhibit Enhanced Migratory and Encephalitogenic Properties in Neuroinflammation
por: Ruck, Tobias, et al.
Publicado: (2013)

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
por: Klotz, Luisa, et al.
Publicado: (2015)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
por: Bryant, Richard J., et al.
Publicado: (2020)

Primary B Cell Lymphoma of the CNS Mimicking Anti-LGI1 Limbic Encephalitis
por: Thomas, Christian, et al.
Publicado: (2018)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
por: Haas, Jürgen, et al.
Publicado: (2019)

MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation
por: Loos, Julia, et al.
Publicado: (2020)

Dichoptic Metacontrast Masking Functions to Infer Transmission Delay in Optic Neuritis
por: Bruchmann, Maximilian, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_au359bu9j59ccffv4468nvj193